# Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development

- Link: https://www.thailand-business-news.com/pr-news/piramal-pharma-solutions-announces-partnership-with-botanix-to-support-drug-substance-development
- Published: 2026-05-18T20:00:00+07:00
- Author: PR Newswire

|   |

 ◦ _Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc.,
   a subsidiary of Botanix Pharmaceuticals Limited, to support the development and
   commercial supply of Sofdra®._
 ◦ _Sofdra is the first and only FDA-approved new chemical entity (NCE) for the 
   treatment of primary axillary hyperhidrosis._
 ◦ _Through this partnership, Piramal Pharma Solutions will leverage the strength
   of its North American drug substance facilities to support robust, consistent
   patient access to Sofdra._

MUMBAI, India, May 18, 2026 /PRNewswire/ — Piramal Pharma Solutions (PPS), a leading
global Contract Development and Manufacturing Organization (CDMO) and part of Piramal
Pharma Ltd_._ (NSE: PPLPHARMA) (BSE: 543635), has entered a manufacturing and supply
arrangement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited(
ABN 70 009 109 755) (ASX:BOT) ("Botanix"), a commercial dermatology company.

 [⌊Peter DeYoung, CEO, Piramal Global Pharma⌉](https://mma.prnasia.com/media2/2981014/Peter_DeYoung_Piramal.jpg?p=medium600)

Peter DeYoung, CEO, Piramal Global Pharma

Under this arrangement, PPS will initiate development and validation services for
Sofpironium Bromide, the active pharmaceutical ingredient (API) in _Sofdra®_, at
its Riverview, Michigan facility. Following successful regulatory approval at Riverview,
PPS and Botanix will consider validating the process at PPS’s Aurora, Canada facility.
This potential twin-site strategy would give Botanix the option to use PPS as a 
dual-source commercial API supplier, enhancing its long-term supply chain flexibility
and security.

With decades of combined experience, the Riverview and Aurora facilities offer exceptional
proficiency in drug substance development and manufacturing, spanning R&D through
commercialization. Recent investments have provided both facilities with the advanced
equipment and unified systems required to execute this program, reinforcing the 
strengths of their geographic proximity and integration expertise while enhancing
their ability to offer cost-efficient solutions.

By maintaining the option for development and validation at both sites, PPS can 
offer partners redundancy, supply chain continuity, and scheduling flexibility. 
If geopolitical issues arise, PPS can seamlessly shift production between facilities,
ensuring ongoing supply for Botanix and its patients. This proactive approach enables
PPS’s partners to remain agile and resilient amid global uncertainty, with robust
coverage across the US and the rest of the world.

These twin-site capabilities also offer financial benefits, enabling PPS’s partners
to better balance quality and time. By derisking the _Sofdra_ supply chain, PPS 
is expected to provide Botanix a significant reduction in cost of goods sold.

"This business partnership demonstrates our ability to deliver tailored, resilient
solutions for organizations like Botanix," said **Peter DeYoung, CEO, Piramal Global
Pharma**. "Our North American drug substance facilities are equipped with the expertise,
advanced technology, and cutting-edge capabilities required to help derisk the _Sofdra_
supply chain and ensure this breakthrough therapy reaches patients in need with 
consistency and efficiency."

This phased approach will enable PPS to support future supply needs for Sofpironium
Bromide while offering the potential for dual-site production if additional capacity
is required. By proactively supporting supply chain continuity, PPS can help improve
the quality of life for patients living with primary axillary hyperhidrosis, underscoring
and reinforcing its commitment to Patient Centricity.

**About Piramal Pharma Solutions**

Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization(
CDMO) offering end-to-end development and manufacturing solutions across the drug
life cycle. We serve our customers through a globally integrated network of facilities
in North America, Europe, and Asia. This enables us to offer a comprehensive range
of services including drug discovery solutions, process and pharmaceutical development
services, clinical trial supplies, commercial supply of APIs, and finished dosage
forms. We also offer specialized services such as the development and manufacture
of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide 
products and services, and potent solid oral drug products. PPS also offers development
and manufacturing services for biologics including vaccines and gene therapies, 
made possible through Piramal Pharma Limited’s associate company, Yapan Bio Private
Limited.

For more information visit: [Piramal Pharma Solutions](https://www.piramalpharmasolutions.com/)
| [LinkedIn](https://www.linkedin.com/company/piramal-pharma-solutions/) | [Facebook](https://www.facebook.com/piramalpharma/)
| [X](https://twitter.com/PiramalPharma)

**About Piramal Pharma Limited**

Piramal Pharma Limited (PPL) (NSE: PPLPHARMA) (BSE: 543635), offers a portfolio 
of differentiated products and services through its 17* global development and manufacturing
facilities and a global distribution network in over 100 countries. PPL includes
Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing
organization; Piramal Critical Care (PCC), a complex hospital generics business;
and the Piramal Consumer Healthcare business, selling over-the-counter consumer 
and wellness products. In addition, one of PPL’s associate companies, Abbvie Therapeutics
India Private Limited, a joint venture between Abbvie and PPL, has emerged as one
of the market leaders in the ophthalmology therapy area in the Indian pharma market.
Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that
operates in the biologics / bio-therapeutics and vaccine segments.

For more information, visit: [Piramal Pharma](https://www.piramalpharma.com/) | 
[LinkedIn](https://in.linkedin.com/company/lifeatpiramalpharma)

* Includes one facility via PPL’s minority investment in Yapan Bio.

**About Botanix Pharmaceuticals **

Botanix Pharmaceuticals Limited (ASX:BOT) is a dermatology company based in Philadelphia
and Phoenix (US) which has received FDA approval for its lead product _Sofdra_™ 
for the treatment of primary axillary hyperhidrosis. _Sofdra_ is the first and only
new chemical entity approved by FDA to treat primary axillary hyperhidrosis and 
presents a novel, safe, and effective solution for patients who have lacked treatment
options for this socially challenging medical condition. 

To learn more please visit: [https://botanixpharma.com/](https://botanixpharma.com/)

Photo: [https://mma.prnasia.com/media2/2981014/Peter_DeYoung_Piramal.jpg?p=medium600](https://mma.prnasia.com/media2/2981014/Peter_DeYoung_Piramal.jpg?p=medium600)

Logo: [https://mma.prnasia.com/media2/1726186/Piramal_Pharma_Solutions_Logo.jpg?p=medium600](https://mma.prnasia.com/media2/1726186/Piramal_Pharma_Solutions_Logo.jpg?p=medium600)

 

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development ](http://www.prnasia.com/story/archive/4960708_EN60708_0?rand=184833)
